70–80 %
of patients who do not receive CINV
prophylaxis experience nausea and/or
vomiting after chemotherapy 2
Medical
complications Affects quality
of life
Significant morbidity, poor
nutrition, muscle wasting,
dehydration, anxiety, physical
damage to the stomach,
discontinuation of anticancer
therapy, compromised
survival outcomes 4–8 Up to 90% of patients
reporting decreased daily
functioning when CINV
prevention is inadequate 5
Initiated and funded by:
in association with: